hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.
The Group’s fast-growing services business includes a unique portfolio of 11+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.
“We run our human challenge trials from the state-of-the-art QMB clinic with our highly specialised on-site virology and immunology laboratory. We have been based at this facility for over 12 years & this is the first clinical facility dedicated to Human Viral Challenge Studies since the closure of the Common Cold Institute in 1990. As the world leaders in human challenge trials, we are delighted to be using this site to help provide end-to-end human challenge trial services for our broad and long-standing client base of global biopharma companies.”
Adam French, VP Clinical Operations at hVIVO
& MEETING ROOMS